HK Stock Market Move | GENFLEET-B(02595) rose over 5% in early trading. GFH375 received its second breakthrough therapy designation.

GENFLEET-B(02595) rose more than 5% in early trading, up 4.55% to 37.2 Hong Kong dollars as of the time of writing, with a turnover of 5.53 million Hong Kong dollars. On the news front, Junfang Pharmaceuticals announced that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by the National Medical Products Administration Drug Evaluation Center, intended for the treatment of KRAS G12D mutant metastatic pancreatic cancer patients who have received at least one previous systemic therapy. This marks the first KRAS G12D inhibitor monotherapy treatment for pancreatic cancer to receive BTD designation in China. Previously, GFH375 became the first KRAS G12D inhibitor to receive BTD designation for non-small cell lung cancer domestically. Overseas clinical studies of GFH375/VS-7375 are being conducted by Junfang's partner Verastem Oncology in the United States, with VS-7375 already qualifying for fast track designation by the US FDA for the treatment of first-line and second-line KRAS G12D mutant pancreatic ductal adenocarcinoma.